INTRODUCTION
============

Alzheimer's disease (AD) is the most common form of dementia in adults, which accounts for an estimated 60 to 80% of dementia cases ([@B49]). The major brain pathological hallmarks of AD are extracellular senile plaques comprised predominantly of amyloid-β (Aβ) peptides, and intraneuronal neurofibrillary tangles (NTFs) comprised of abnormally hyperphosphorylated tau. The hyperphosphorylated tau loses its activity to bind to microtubules and to promote microtubule assembly, and instead disrupts microtubules ([@B23], [@B24]).

The majority of AD cases have the sporadic form of the disease. Sporadic AD is multifactorial and may involve several different etiopathogenic mechanisms. It is well established that elderly individuals are at increased risk of cognitive decline after anesthesia or surgery ([@B32]; [@B40]; [@B33]). Though the long-term effect of anesthesia on cognition is still under debate, anesthesia may accelerate preexisting but asymptomatic neurodegenerative changes in the brain and thus promote the development of AD ([@B34]). Evidence from animal models suggests that anesthetic exposure can increase Aβ plaque formation and tau hyperphosphorylation ([@B38]; [@B4]; [@B36]; [@B45]; [@B16]), and cause significant learning and memory deficits in aged rodents ([@B11], [@B12]; [@B4]; [@B26]; [@B47]).

Impaired brain insulin signaling pathway has been implicated in the development of AD ([@B9]; [@B13]). We also found decreases in the levels and activities of several components of the insulin signaling pathway in AD ([@B29]). In agreement with the proposed role of insulin signaling in cognition, intranasal administration of insulin has been reported to improve memory in healthy humans ([@B2], [@B3]) and in individuals with mild cognitive impairment and AD ([@B42], [@B43]; [@B10]). Animal studies also show improved general behavioral performance and cognition in normal and diabetic mice after treatment with intranasal insulin ([@B17]; [@B30]). It has also been reported that insulin can affect with the stability, production, degradation and aggregation of Aβ, leading to reduced neurotoxicity ([@B39]; [@B14]; [@B15]). However, whether intranasal insulin treatment prevents or ameliorates anesthesia-induced tau hyperphosphorylation, which is crucial to neurodegeneration, has not been reported.

In the present study, we treated 3xTg-AD mice, a commonly used transgenic model of AD which harbors three mutated transgenes (human PS1~M146V~, APP~SWE~, and tau~P301L~), with propofol, a commonly used intravenous anesthetic in clinical practice, and investigated the effects of intranasal insulin on propofol-induced hyperphosphorylation of tau. We found that insulin attenuated propofol-induced hyperphosphorylation of tau, which may be mainly through up-regulation of protein phosphatase 2A (PP2A) and down-regulation of several tau protein kinases.

MATERIALS AND METHODS {#s1}
=====================

ANTIBODIES AND REAGENTS
-----------------------

Primary antibodies used in this study are listed in **Table [1](#T1){ref-type="table"}**. Peroxidase-conjugated anti-mouse and anti-rabbit IgG were obtained from Jackson Immuno Research Laboratories (West Grove, PA, USA). The enhanced chemiluminescence (ECL) kit was from Pierce (Rockford, IL, USA). The ABC staining system was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Propofol was purchased from MP Biomedicals (Solon, OH, USA). Insulin (Humulin R U-100) was from Eli Lily (Indianapolis, IN, USA). Other chemicals were from Sigma-Aldrich (St. Louis, MO, USA).

###### 

Primary antibodies used in this study.

  Antibody        Type    Specificity     Phosphorylation sites                       Source/reference
  --------------- ------- --------------- ------------------------------------------- -----------------------------------------------
  IRβ             Poly-   IRβ                                                         Cell Signaling Technology, Danvers, MA
  IGF-1Rβ         Poly-   IGF-1Rβ                                                     Cell Signaling Technology
  P-IRβ/IGF-1Rβ   Mono-   P-IRβ/IGF-1Rβ   Tyr1150/1151(IRβ), Tyr1135/1136 (IGF-1Rβ)   Cell Signaling Technology
  IRS1            Poly-   IRS1                                                        Cell Signaling Technology
  IRS1 pS307      Poly-   P-IRS1          Ser307                                      Cell Signaling Technology
  PI3K p85        Poly-   PI3K (p85)                                                  Cell Signaling Technology
  P-PI3K p85      Poly-   P-PI3K (p85)    Tyr458/Tyr199                               Cell Signaling Technology
  PDK1            Poly-   PDK1                                                        Cell Signaling Technology
  PDK1 pS241      Poly-   P-PDK1          Ser241                                      Cell Signaling Technology
  AKT             Poly-   AKT                                                         Cell Signaling Technology
  AKT pS473       Poly-   P-AKT           Ser473                                      Cell Signaling Technology
  AKT pT308       Poly-   P-AKT           Thr308                                      Cell Signaling Technology
  GSK-3β pS9      Poly-   P-GSK-β         Ser9                                        Cell Signaling Technology
  GSK-3α/β        Poly-   GSK-3β                                                      Cell Signaling Technology
  R134d           Poly-   Tau                                                         [@B48]
  pS199           Poly-   P-tau           Ser199                                      Invitrogen, Grand Island, NY
  pT205           Poly-   P-tau           Thr205                                      Invitrogen
  pT212           Poly-   P-tau           Thr212                                      Invitrogen
  pS214           Poly-   P-tau           Ser214                                      Invitrogen
  pT231           Poly-   P-tau           Thr231                                      Invitrogen
  pS262           Poly-   P-tau           Ser262                                      Invitrogen
  12E8            Mono-   P-tau           Ser262/356                                  Dr. D. Schenk
  PHF-1           Mono-   P-tau           Ser396/404                                  Dr. P. Davies
  pS409           Poly-   P-tau           Ser409                                      Invitrogen
  pS422 (R145)    Poly-   P-tau           Ser422                                      [@B35]
  CaMKII          Mono-   CaMKII                                                      Promega, Madison, WI
  CaMKII(pT286)   Poly-   P-CaMKII        Thr286                                      Promega
  JNK             Poly-   JNK                                                         Cell Signaling Technology
  P-JNK           Poly-   P-JNK           Thr183/Tyr185                               Cell Signaling Technology
  ERK1/2          Mono-   ERK1/2                                                      Cell Signaling Technology
  P-ERK1/2        Poly-   P-ERK1/2                                                    Cell Signaling Technology
  CDK5            Poly-   CDK5                                                        Santa Cruz Biotechnology
  P35             Poly-   P35                                                         Santa Cruz Biotechnology
  PP2A-C          Mono-   PP2A-C                                                      BD Bioscience, Palo Alto, CA
  Methyl-PP2A-C   Mono-   Methyl-PP2A-C                                               Millipore, Temecula, CA
  PP2A pY307      Poly-   P-PP2A          Tyr307                                      Santa Cruz Biotechnology, Santa Cruz, CA, USA
  Anti-GAPDH      Poly-   GAPDH                                                       Santa Cruz Biotechnology

ANIMALS AND ANIMAL TREATMENTS
-----------------------------

The breeding pairs of the homozygous 3xTg-AD mouse harboring PS1~M146V~, APP~Swe~, and tau~P301L~ transgenes and the wild type (WT) control mouse (a hybrid of 129/Sv and C57BL/6 mice) were initially obtained from Dr. F. M. LaFerla through Jackson Laboratory (New Harbor, 124 ME, USA), and the mice were bred in our institutional animal colony. Mice were housed (4\~5 animals per cage) with a 12/12 h light/dark cycle and with ad libitum access to food and water. The housing, breeding, and animal experiments were in accordance with the approved protocol from our Institutional Animal Care and Use Committee, according to the PHS Policy on Human Care and Use of Laboratory animals (revised March 15, 2010).

The 3xTg-AD mice and WT mice (female, 9 months old) used for the present study were habituated to handling for 14 days prior to the experiment. Female mice were used because the female 3xTg-AD mice develop behavioral deficits faster than the male mice ([@B8]). The selection of the age of 9 months was because the 3xTg-AD mice at this age show neurogenic and neuroplastic deficits but no NFTs or amyloid plaques and are cognitively impaired ([@B5]; [@B8]; [@B31]; [@B6]). Intranasal delivery was carried out manually without anesthesia while the mouse head was restrained in a supine position with the neck in extension, as described ([@B30]). A total of 1.75U/17.5 μl insulin or 0.9% saline (Veh 1) was delivered over both nares alternatively using a 10 μl Eppendorf pipetter. The mouse was held for an additional 5--10 s to ensure the fluid was inhaled. The successful nasal delivery by using this approach was confirmed by examination of ink in the autopsied brains after nasal delivery with ink using the same approach (data not shown). All mice were treated with insulin or, as a control, saline daily for seven consecutive days. Thirty minutes following the last dose, the mice were injected intraperitoneally (i.p.) with propofol dissolved in intralipid (250 mg/kg body weight) or the equivalent amount of intralipid (Veh 2), followed by sacrifice of the animals 30 min or 2 h later (**Figure [1](#F1){ref-type="fig"}**). The brains were removed immediately, and the rostral halves (separated coronally at the bregma level) of the mouse brains were dissected, flash frozen in dry ice, and stored at -80°C for biochemical analyses at a later date.

![**Animal study design**.](fnagi-06-00100-g001){#F1}

WESTERN BLOT ANALYSIS
---------------------

Mouse brain tissue was homogenized in pre-chilled buffer containing 50 mM Tris-HCl (pH 7.4), 50 mM GlcNAc, 20 μM UDP, 2.0 mM EGTA, 2 mM Na~3~VO~4~, 50 mM NaF, 20 mM Glycero-phosphate, 0.5 mM AEBSF, 10 μg/ml aprotinin, 10 μg/ml leupeptin, and 4 μg/ml pepstatin A. Protein concentrations of the homogenates were determined by using modified Lowery method. The samples were resolved in 10 or 12.5% SDS-PAGE and electro-transferred onto Immobilon-P membrane (Millipore, Bedford, MA, USA). The blots were then probed with primary antibody and developed with the corresponding horseradish peroxidase-conjugated secondary antibody and ECL kit (Pierce, Rockford, IL, USA). Densitometrical quantification of protein bands in Western blots were analyzed by using the TINA software (Raytest IsotopenmeBgerate GmbH, Straubenhardt, Germany).

IMMUNOHISTOCHEMICAL STAINING
----------------------------

Floating sagittal sections were incubated at room temperature in 0.3% H~2~O~2~ for 30 min and then in 0.3% Triton X-100 for 15 min, washed in PBS, and blocked in a solution containing 5% normal goat serum and 0.1% Triton X-100 for 30 min. Sections were then incubated at 4°C with primary antibody overnight, followed by incubation with biotinylated secondary antibody and avidin/biotinylated horseradish peroxidase (Santa Cruz Biotechnology). The sections were stained with peroxidase substrate and then mounted on microscope slides (Brain Research Laboratories, Newton, MA, USA), dehydrated, and covered with cover slips.

STATISTICAL ANALYSIS
--------------------

For biochemical analyses, data were analyzed by one-way ANOVA followed by Tukey's post hoc tests or unpaired two-tailed *t* tests, using Graph pad. All data are presented as means ± SEM, and *p* \< 0.05 was considered statistically significant.

RESULTS
=======

PROPOFOL EXACERBATES HYPERPHOSPHORYLATION OF TAU AT MULTIPLE SITES IN 3XTG-AD MICE
----------------------------------------------------------------------------------

We first verified the effect of propofol treatment on tau phosphorylation by using Western blots developed with phosphorylation-dependent and site-specific tau antibodies, which detect tau phosphorylation at Thr181, Ser199, Thr205, Thr212, Thr231, Ser262/356 (12E8 sites), Ser396/404 (PHF-1 sites), Ser409 and Ser422. As expected, we observed a marked increase in tau phosphorylation at all the above phosphorylation sites except Ser422 both 30 min and 2 h after propofol injection (**Figure [2](#F2){ref-type="fig"}**). Quantitative analyses indicated that the increase of tau phosphorylation was most dramatic at Thr181, Thr205, Thr212, Ser262/356 (12E8 sites), and Ser396/404 (PHF-1 sites; **Figures [2B](#F2){ref-type="fig"}, [C](#F2){ref-type="fig"}**). The phosphorylation of tau at several sites was higher at 2 h than 30 min post anesthesia. Up-shift of the apparent gel mobility of tau, which is a well-established phenomenon of tau hyperphosphorylation ([@B25]; [@B27]), was also seen (**Figure [2A](#F2){ref-type="fig"}**). These results confirmed marked increase in tau phosphorylation in mice anesthetized with propofol.

![**Tau hyperphosphorylation at various AD-related sites in the brains of 3xTg-AD mice after anesthesia with propofol. (A)** Homogenates of the rostral halves of brains from 3xTg-AD mice sacrificed 30 min or 2 h following intraperitoneal injection of propofol were analyzed by Western blots developed with antibody R134d against total tau and several phosphorylation-dependent and site-specific tau antibodies, as indicated in the middle of the blots. **(B,C)** Densitometrical quantifications (mean ± SEM, *n* = 6/group) of the blots after being normalized with the corresponding total tau level **(B)** or with the GAPDH level **(C)**. The levels of the 3xTg-veh1/veh2 group were set to 100. \**p* \< 0.05 vs. vehicle-injected 3xTg-AD mice.](fnagi-06-00100-g002){#F2}

Hypothermia is known to be a major factor underlying anesthesia-induced tau hyperphosphorylation ([@B38]; [@B46]). Therefore, we determined the rectal temperature of the mice. We found that the average temperature dropped from around 38.2 to 28.6°C within 30 min after propofol injection (**Figure [3](#F3){ref-type="fig"}**), which is consistent with previous reports ([@B38]; [@B46]). The average rectal temperature dropped further to 25.6°C 2 h after propofol injection when the mice had not woken from anesthesia. We did not prevent the anesthesia-induced hypothermia because the objective of this study is to evaluate intranasal insulin's efficacy in the prevention of hyperphosphorylation of tau, rather than to investigate the role of hypothermia in propofol-induced brain changes, which have been reported previously ([@B38]; [@B46]).

![**Alteration of rectal temperature during anesthesia of the 3xTg-AD mice**.](fnagi-06-00100-g003){#F3}

INTRANASAL INSULIN ATTENUATES PROPOFOL-INDUCED TAU HYPERPHOSPHORYLATION
-----------------------------------------------------------------------

Insulin is neuroprotective, and intranasal delivery is a non-invasive and effective way for insulin to reach the brain without affecting the peripheral blood glucose level ([@B41]). In order to investigate the effect of insulin on propofol-induced hyperphosphorylation of tau, we delivered insulin intranasally to 3xTg-AD mice for 7 days prior to the administration of propofol. We observed that mice receiving daily intranasal insulin (3xTg-ins/prop group) for 7 days before anesthesia had significantly lower phosphorylation level of tau at Thr212, Ser262/356 (12E8 sites), Ser396/404 (PHF-1 sites), and Ser409 at 30 min following propofol injection when compared to mice receiving saline (vehicle) only (3xTg-veh1/prop; **Figures [4A](#F4){ref-type="fig"}, [C](#F4){ref-type="fig"}**). The phosphorylation level of tau at other epitopes studied (Thr181, Ser199, Thr205, Thr231, and ser422) was also lower in the insulin-treated group than the untreated group, but the decreases did not reach statistical significance (**Figure [4C](#F4){ref-type="fig"}**). Similar preventive role of insulin against propofol-induced tau phosphorylation was also seen 2 h following propofol injection (**Figures [4B](#F4){ref-type="fig"}, [D](#F4){ref-type="fig"}**). The prevention of tau phosphorylation by insulin was confirmed immunohistochemically by using monoclonal antibodies 12E8 and PHF-1 against phosphorylated tau. We found that the number of strongly stained neurons in the mouse brains was markedly reduced in the 3xTg-ins/prop group as compared to the 3xTg-veh1/prop group (**Figure [4E](#F4){ref-type="fig"}**). These results indicate that intranasal insulin administration attenuates propofol-induced tau hyperphosphorylation in the mouse brain. The insulin's action in attenuation of propofol-induced tau hyperphosphorylation was not related to hypothermia because no difference in the body temperature between the insulin-treated and untreated mice was observed (**Figure [3](#F3){ref-type="fig"}**).

![**Effect of intranasal insulin treatments on propofol-induced tau phosphorylation. (A,B)** Homogenates of the rostral halves of brains from 3xTg-veh1/prop and 3xTg-ins/prop mice sacrificed 30 min **(A)** or 2 h **(B)** following intraperitoneal injection of propofol were analyzed by Western blots developed with antibody R134d against total tau and several phosphorylation-dependent and site-specific tau antibodies, as indicated. **(C,D)** Densitometrical quantifications (mean ± SEM, *n* = 6/group) of the blots after being normalized with the corresponding total tau level. \**p* \< 0.05. **(E)** Immunohistochemical staining of the brain tissue sections (frontal cortex) of mice sacrificed 30 min after propofol treatment. Monoclonal antibodies 12E8 and PHF-1 recognizes tau phosphorylated at Ser262/Ser356 and Ser396/Ser404, respectively.](fnagi-06-00100-g004){#F4}

INTRANASAL INSULIN ENHANCES BRAIN INSULIN SIGNALING
---------------------------------------------------

To understand the possible mechanism of the beneficial effect of intranasal insulin treatment on tau hyperphosphorylation, we investigated its effect on insulin signaling in the mouse brain by comparing the level and activation of each component of the signaling pathway, including insulin receptor β (IRβ), insulin-like growth factor-1 receptor β (IGF-1Rβ), insulin receptor substrate-1 (IRS-1), phosphatidylinositide 3-kinases (PI3K), 3-phosphoinositide-dependent protein kinase-1 (PDK1) and protein kinase B (AKT). The activation of these proteins was assessed by measuring their phosphorylation levels at the activity-dependent sites. We found that insulin signaling pathway was disturbed in the brains of 3xTg-AD mice (**Figures [5A](#F5){ref-type="fig"}, [B](#F5){ref-type="fig"}**, 3xTg-veh1/veh2 vs. WT-veh1/veh2). Propofol further disturbed the insulin signaling, as evidenced by down-regulation of the level of PI3K p55 pY199 and PDK1 and up-regulation of the level of PI3K p85 pY458 and AKT pS473 (**Figures [5A](#F5){ref-type="fig"}, [B](#F5){ref-type="fig"}**). The dramatic increase in AKT pS473 might result from a cross-talk with other signaling pathway activated by propofol. We observed that intranasal delivery of insulin for 7 days prior to the administration of propofol enhanced the insulin signaling transduction in the brain. The levels of IRβ, IGF-1Rβ, IRβ pY1150/1151, IRS1 pS307, PI3K p85 pY458, PI3K p55 pY199, PDK1, AKT, and AKT pT308 were all up-regulated in the 3xTg-ins/prop mice as compared to the 3xTg-veh1/prop mice (**Figure [5](#F5){ref-type="fig"}**). These results indicate that intranasal insulin promotes brain insulin signaling.

![**Effect of propofol and intranasal insulin treatment on brain insulin signaling**. Homogenates of the rostral halves of brains from mice sacrificed 30 min following propofol injection were analyzed by Western blots developed with the indicated antibodies. The blots were then quantified densitometrically, and the data are presented as mean ± SEM (*n* = 6/group), where the values of the 3xTg-veh1/veh2 group were set as 100%. ^&^*p* \< 0.05 vs. WT-veh1/veh2 group; ^\#^*p* \< 0.05 vs. 3xTg-veh1/veh2 group; ^\$^*p* \< 0.05 vs. 3xTg-veh1/prop group.](fnagi-06-00100-g005){#F5}

INTRANASAL INSULIN UP-REGULATES PP2A IN THE BRAIN
-------------------------------------------------

Down-regulation of PP2A, a major tau phosphatase in the brain ([@B28]), was shown to underlie anesthesia-induced hyperphosphorylation of tau ([@B38]). To investigate whether PP2A also mediates insulin's activity to attenuate propofol-induced tau hyperphosphorylation, we determined the level of the catalytic subunit of PP2A (PP2A-C) and its methylation, which enhances PP2A activity ([@B20]), and tyrosine-phosphorylation at Tyr307, which inhibits its activity ([@B7]). We observed that intranasal insulin treatment led to a significant increase in the level and the methylation of PP2A in the mouse brain (**Figures [6A](#F6){ref-type="fig"}, [B](#F6){ref-type="fig"}**). However, the net PP2A methylation, as quantified after normalization with the PP2A-C level, was not increased (**Figure [6C](#F6){ref-type="fig"}**), suggesting that the increased total PP2A methylation is due to the increase of PP2A-C level. These results suggest that intranasal insulin might attenuate propofol-induced tau hyperphosphorylation through an increase of methylated PP2A-C and thus its activity in the brain.

![**Effect of propofol and intranasal insulin treatments on PP2A. (A)** Homogenates of the rostral halves of mouse brains were analyzed by Western blots developed with antibodies indicated at the left side of the blots. **(B,C)** Densitometrical quantifications (mean ± SEM, *n* = 6/group) of the blots after normalization with the GAPDH levels **(B)** or with the PP2A-C levels **(C)**. ^\$^*p* \< 0.05 vs. 3xTg-veh1/prop group.](fnagi-06-00100-g006){#F6}

ACTIVITIES OF SEVERAL TAU KINASES ARE ALTERED IN THE MOUSE BRAIN AFTER PROPOFOL AND INTRANASAL INSULIN TREATMENTS
-----------------------------------------------------------------------------------------------------------------

Besides PP2A, tau phosphorylation is also regulated by several protein kinases ([@B50]). The levels of several tau protein kinases have been reported to be altered after anesthesia ([@B38]; [@B46]). We therefore determined the levels of the total and the activated form of several tau protein kinases, including glycogen synthase kinase-3β (GSK-3β), mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK), cyclin-dependent kinase 5 (cdk5), calcium/calmodulin-dependent protein kinase II (CaMKII), and c-Jun N-terminal kinase (JNK). Consistent with previous studies ([@B38]; [@B46]), we found a dramatic increase in the inhibitory Ser9 phosphorylation of GSK-3β and moderate alterations of a few other tau kinases after anesthesia with propofol (**Figure [7](#F7){ref-type="fig"}**). Intranasal insulin treatment resulted in mild to moderate reductions of CDK5, CaMKII pT286, and JNK pT184/pY185 in the propofol-treated mouse brains. These results suggest that the insulin-induced reduction of these three tau kinases might also contribute to insulin's role in attenuation of propofol-induced tau hyperphosphorylation.

![**Effect of propofol and intranasal insulin treatments on tau kinases. (A)** Homogenates of the rostral halves of mouse brains were analyzed by Western blots developed with antibodies indicated at the left side of the blots. **(B,C)** Densitometrical quantifications (mean ± SEM, *n* = 6/group) of the blots after being normalized with the GAPDH levels **(B)** or with the levels of the corresponding total protein kinase level **(C)**. ^\#^*p* \< 0.05 vs. 3xTg-veh1/veh2 group; ^\$^*p* \< 0.05 vs. 3xTg-veh1/prop group.](fnagi-06-00100-g007){#F7}

DISCUSSION
==========

Tau is the major microtubule-associated protein of mature neurons. Its major known physiological activity is to promote the assembly of tubulin into microtubules and to stabilize microtubule structure. Abnormally hyperphosphorylated tau fails to bind to tubulin and also gains a toxic activity of disrupting microtubules ([@B23]; [@B1]). Therefore, abnormal hyperphosphorylation of tau appears to be crucial to neurodegeneration in AD and other tauopathies ([@B19]). The vital role of tau in neurodegeneration have been further supported by several recent in vivo studies showing that tau knockout reduces or eliminates neurodegeneration and behavioral deficits in transgenic mouse models of AD ([@B44]; [@B18]).

Many epidemiological studies have demonstrated that general anesthesia induces memory loss and increases the risk for dementia and AD ([@B34]). In an effort to understand the possible underlying mechanisms, several studies have found that both intravenous and inhalational anesthetics induce hyperphosphorylation of tau in the brain ([@B22]; [@B38]; [@B46], [@B45]; [@B26]). These studies suggest an important molecular mechanism by which anesthesia may induces memory loss and increases the risk for dementia and AD through promoting abnormal hyperphosphorylation of tau and consequently neurodegeneration ([@B37]; [@B46]; [@B26]).

[@B38] reported that anesthetics induced hyperphosphorylation of tau as a consequence of PP2A inhibition by hypothermia. Subsequently, two distinct underlying mechanisms were found: one associating with activation of stress-activated protein kinases and the other resulting from anesthesia-induced hypothermia ([@B46]; [@B51]). In consistent with previous reports, we found, in the present study, a marked increase in tau phosphorylation at several AD-related sites after 3xTg-AD mice were anesthetized with propofol. Furthermore, tau hyperphosphorylation was accompanied with activation of JNK but inhibition of GSK-3β and ERK after anesthesia with propofol. These findings are consistent with previous observations showing activation of JNK and marked inhibition of GSK-3β and ERK in WT mice after anesthesia ([@B38], [@B37]; [@B46]; [@B26]).

Drug administration into the brain through intranasal delivery, which was first introduced by Dr. W. H. Frey, bypasses the blood brain barrier and has been used successfully in animal studies and clinical trials in humans ([@B41], [@B43]; [@B17]; [@B21]; [@B30]; [@B10]; [@B52]). Intranasal administration of insulin has an additional advantage that it does not interfere with the insulin level or glucose metabolism in the periphery ([@B41]). Thus, in the present study we selected this approach to investigate whether insulin prevents or ameliorates anesthesia-induced tau hyperphosphorylation. We found that daily administration of insulin for a week significantly prevented propofol-induced tau hyperphosphorylation at several AD-related sites. Furthermore, the insulin's preventive role might result from its promotion of brain insulin signaling and PP2A and down-regulation of several tau protein kinases, CDK5, CaMKII, and JNK. Although hypothermia was observed in the 3xTg-AD mice after anesthesia with propofol, the insulin's preventive role does not seem to be associated with hypothermia because pre-treatment of mice with intranasal insulin did not affect propofol-induced hypothermia. Our present findings provide important experimental evidence supporting that intranasal insulin treatment might be used for preventing anesthesia-induced risk for memory loss and dementia.

In summary, we have found that anesthesia with propofol exacerbated hyperphosphorylation of tau at multiple AD-related phosphorylation sites in the brain of 3xTg-AD mice. These findings provide experimental evidence supporting the role of anesthesia in increasing the risk for dementia and AD in vulnerable individuals and demonstrate that anesthesia could be a significant factor for AD in those elderly individuals who have received general anesthesia. Furthermore, we found, for the first time, that intranasal administration of insulin for a week prior to anesthesia significantly prevented propofol-induced tau hyperphosphorylation and enhanced brain insulin signaling. These findings provide the first evidence supporting that intranasal insulin might be a promising treatment for prevention of anesthesia-induced memory loss and increased risk for AD and dementia.
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